Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun-Feng Liu

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
Current Medical Research and Opinion|October 5, 2020
Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world settingYan He, Xue-Min Gao, Lei Li, et al.
Thoracic Cancer|July 20, 2024
Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in ChinaYong Li, Wei-Xin Liu, Ling Qi, et al.
World Journal of Gastroenterology|January 13, 2004
Long-term outcome of esophageal myotomy for achalasiaJun-Feng Liu, Jun Zhang, Zi-Qiang Tian, et al.
Molecular Plant Pathology|September 17, 2025
Structural Insights Into the Role of RxLR Effectors in the Arms Race Between Oomycetes and PlantsYang Liu, Yang Yang Zheng, Xin Ru Zhou, et al.
Injury|June 13, 2020
Dynamic limited axial compression yields favorable functional outcomes in the fixation of Pauwels type-3 femoral neck fractures: A retrospective cohort studyJun-Feng Liu, Shao-Di Zhang, Liang Huang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 29, 2009
[Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection]Wei Liu, Xi-Shan Hao, Qian Fan, et al.
Hepatology International|February 17, 2026
TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort studyXue-Gang Yang, Li-Wei Deng, Yong Zhao, et al.
Cancer Management and Research|July 2, 2020
Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled TrialYu-Tao Liu, Xue-Zhi Hao, De-Ruo Liu, et al.
Frontiers in Immunology|April 27, 2026
Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching studyLi-Wei Deng, Jun-Feng Liu, Hai-Yan Yu, et al.
European Journal of Radiology|September 5, 2025
Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational studyLi-Wei Deng, Qing-Yun Xie, Bo Peng, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Current Medical Research and Opinion|October 5, 2020
Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world settingYan He, Xue-Min Gao, Lei Li, et al.
Thoracic Cancer|July 20, 2024
Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in ChinaYong Li, Wei-Xin Liu, Ling Qi, et al.
World Journal of Gastroenterology|January 13, 2004
Long-term outcome of esophageal myotomy for achalasiaJun-Feng Liu, Jun Zhang, Zi-Qiang Tian, et al.
Molecular Plant Pathology|September 17, 2025
Structural Insights Into the Role of RxLR Effectors in the Arms Race Between Oomycetes and PlantsYang Liu, Yang Yang Zheng, Xin Ru Zhou, et al.
Injury|June 13, 2020
Dynamic limited axial compression yields favorable functional outcomes in the fixation of Pauwels type-3 femoral neck fractures: A retrospective cohort studyJun-Feng Liu, Shao-Di Zhang, Liang Huang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 29, 2009
[Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection]Wei Liu, Xi-Shan Hao, Qian Fan, et al.
Hepatology International|February 17, 2026
TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort studyXue-Gang Yang, Li-Wei Deng, Yong Zhao, et al.
Cancer Management and Research|July 2, 2020
Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled TrialYu-Tao Liu, Xue-Zhi Hao, De-Ruo Liu, et al.
Frontiers in Immunology|April 27, 2026
Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching studyLi-Wei Deng, Jun-Feng Liu, Hai-Yan Yu, et al.
European Journal of Radiology|September 5, 2025
Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational studyLi-Wei Deng, Qing-Yun Xie, Bo Peng, et al.
Pageof 16